Regeneron Pharmaceuticals, Inc. $REGN Shares Purchased by Howland Capital Management LLC

Howland Capital Management LLC lifted its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 6.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 37,860 shares of the biopharmaceutical company’s stock after purchasing an additional 2,175 shares during the period. Regeneron Pharmaceuticals comprises approximately 1.1% of Howland Capital Management LLC’s portfolio, making the stock its 26th largest position. Howland Capital Management LLC’s holdings in Regeneron Pharmaceuticals were worth $29,223,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of the company. Ellerson Group Inc. ADV increased its stake in shares of Regeneron Pharmaceuticals by 49.2% during the third quarter. Ellerson Group Inc. ADV now owns 8,102 shares of the biopharmaceutical company’s stock worth $4,556,000 after acquiring an additional 2,671 shares during the period. Nordea Investment Management AB grew its position in shares of Regeneron Pharmaceuticals by 118.1% in the fourth quarter. Nordea Investment Management AB now owns 137,321 shares of the biopharmaceutical company’s stock valued at $105,810,000 after purchasing an additional 74,350 shares during the last quarter. TD Asset Management Inc boosted its position in Regeneron Pharmaceuticals by 15.9% during the third quarter. TD Asset Management Inc now owns 374,264 shares of the biopharmaceutical company’s stock worth $210,437,000 after acquiring an additional 51,407 shares during the last quarter. Wealthfront Advisers LLC boosted its position in Regeneron Pharmaceuticals by 28.7% during the third quarter. Wealthfront Advisers LLC now owns 5,940 shares of the biopharmaceutical company’s stock worth $3,340,000 after acquiring an additional 1,325 shares during the last quarter. Finally, Krilogy Financial LLC acquired a new stake in Regeneron Pharmaceuticals during the third quarter worth approximately $1,176,000. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN opened at $612.14 on Friday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.96 and a current ratio of 3.57. The company has a market capitalization of $64.72 billion, a PE ratio of 14.92, a PEG ratio of 1.34 and a beta of 0.25. The company’s 50 day moving average price is $692.11 and its 200 day moving average price is $738.16. Regeneron Pharmaceuticals, Inc. has a 52 week low of $503.25 and a 52 week high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $8.91 by $0.56. The firm had revenue of $3.61 billion during the quarter, compared to analysts’ expectations of $3.48 billion. Regeneron Pharmaceuticals had a net margin of 29.65% and a return on equity of 13.16%. The company’s revenue was up 19.0% compared to the same quarter last year. During the same period in the previous year, the company earned $8.22 earnings per share. Research analysts expect that Regeneron Pharmaceuticals, Inc. will post 37.44 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, June 4th. Shareholders of record on Wednesday, May 20th were paid a $0.94 dividend. The ex-dividend date was Wednesday, May 20th. This represents a $3.76 dividend on an annualized basis and a yield of 0.6%. Regeneron Pharmaceuticals’s payout ratio is 9.16%.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other news, Director Arthur F. Ryan sold 100 shares of the business’s stock in a transaction on Friday, May 1st. The shares were sold at an average price of $705.24, for a total value of $70,524.00. Following the completion of the sale, the director directly owned 17,503 shares in the company, valued at approximately $12,343,815.72. The trade was a 0.57% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 6.97% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the stock. Guggenheim increased their price target on shares of Regeneron Pharmaceuticals from $975.00 to $995.00 and gave the stock a “buy” rating in a research note on Friday, May 1st. Wells Fargo & Company dropped their price target on shares of Regeneron Pharmaceuticals from $800.00 to $700.00 and set an “equal weight” rating on the stock in a research note on Monday, May 18th. Citigroup downgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their price target for the stock from $900.00 to $700.00 in a research note on Monday, May 18th. Canaccord Genuity Group decreased their price objective on shares of Regeneron Pharmaceuticals from $1,057.00 to $875.00 and set a “buy” rating for the company in a report on Tuesday, May 19th. Finally, BMO Capital Markets decreased their price target on shares of Regeneron Pharmaceuticals from $900.00 to $730.00 and set an “outperform” rating for the company in a report on Monday, May 18th. Two research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and ten have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $792.65.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.